October 17, 2023
Company Description: NFlection is a clinical stage biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevi sebacei. To address these disorders, which are also referred to as RASopathies because they are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, we are developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors for topical treatment of these conditions.
CEO/Top Company Official
Lead Product in Development
Development Phase of Primary Product
Number Of Unlicensed Products